Tern Plc confirms no banking relationship with Silicon Valley Bank

TERN Plc

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, provides the following statement regarding Silicon Valley Bank and Silicon Valley Bank UK Limited.

Tern confirms that the Company has no banking relationship, or other financing arrangements, with SVB.

While Tern Plc continues to monitor the SVB situation and its effect on Tern’s portfolio companies, the Directors of Tern do not currently believe that any of the portfolio companies’ exposure to SVB will have a significant impact on the net asset value of Tern.

Further announcements will be made, as necessary and appropriate, in due course.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search